Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate

doi:10.1016/j.ijrobp.2006.12.051

Title: Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate

Full Record
Other Related Research

Abstract

Purpose: To examine the pathophysiologic impact of treatment with combretastatin A4 phosphate (CA4P) in regions of tumors that ultimately either necrose or survive treatment with this agent. Methods and Materials: Proliferation, perfusion, vessel density, and expression of vascular endothelial growth factor (VEGF) were analyzed in the KHT tumor model after treatment with CA4P. Analyses were conducted in the whole tumor and the tumor periphery. Results: Perfusion in the tumor periphery decreased 4 h after treatment, but returned to baseline 20 h later. Whole-tumor perfusion also decreased 4 h after treatment, but did not return to baseline. Vessel density decreased in the tumor as a whole, but not in the tumor periphery. No significant effect on the expression of VEGF was observed, but a decrease in proliferation in the whole tumor and the periphery was noted. Conclusions: The present study shows that those areas of a tumor that survive treatment with CA4P are affected by CA4P exposure, though only transiently. The decrease in perfusion could negatively affect therapies utilizing the combination of CA4P and conventional anticancer agents by decreasing drug delivery and tissue oxygenation. These findings suggest that the timing of CA4P treatments when used in conjunction with conventional anticancer therapiesmore » should be considered carefully.« less

Authors:

Salmon, Beth A. ^[1]; Siemann, Dietmar W. ^[2]

Department of Pharmacology and Therapeutics, Shands Cancer Center, University of Florida, Gainesville, FL (United States)
Department of Pharmacology and Therapeutics, Shands Cancer Center, University of Florida, Gainesville, FL (United States) and Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL (United States). E-mail: siemadw@ufl.edu

Publication Date:: Tue May 01 00:00:00 EDT 2007

OSTI Identifier:: 20951635

Resource Type:: Journal Article

Resource Relation:: Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 68; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.12.051; PII: S0360-3016(07)00091-0; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; BIOMEDICAL RADIOGRAPHY; DRUGS; GROWTH FACTORS; PHOSPHATES; SARCOMAS; THERAPY

Citation Formats


                    Salmon, Beth A., and Siemann, Dietmar W.. Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate.  United States: N. p., 2007. 
        Web.  doi:10.1016/j.ijrobp.2006.12.051.

Copy to clipboard


                    Salmon, Beth A., & Siemann, Dietmar W.. Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate.  United States.  doi:10.1016/j.ijrobp.2006.12.051.

Copy to clipboard


                    Salmon, Beth A., and Siemann, Dietmar W.. Tue .  
        "Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate".  United States.  
        doi:10.1016/j.ijrobp.2006.12.051.

Copy to clipboard


                    
@article{osti_20951635,

  title        = {Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate},

  author       = {Salmon, Beth A. and Siemann, Dietmar W.},

  abstractNote = {Purpose: To examine the pathophysiologic impact of treatment with combretastatin A4 phosphate (CA4P) in regions of tumors that ultimately either necrose or survive treatment with this agent. Methods and Materials: Proliferation, perfusion, vessel density, and expression of vascular endothelial growth factor (VEGF) were analyzed in the KHT tumor model after treatment with CA4P. Analyses were conducted in the whole tumor and the tumor periphery. Results: Perfusion in the tumor periphery decreased 4 h after treatment, but returned to baseline 20 h later. Whole-tumor perfusion also decreased 4 h after treatment, but did not return to baseline. Vessel density decreased in the tumor as a whole, but not in the tumor periphery. No significant effect on the expression of VEGF was observed, but a decrease in proliferation in the whole tumor and the periphery was noted. Conclusions: The present study shows that those areas of a tumor that survive treatment with CA4P are affected by CA4P exposure, though only transiently. The decrease in perfusion could negatively affect therapies utilizing the combination of CA4P and conventional anticancer agents by decreasing drug delivery and tissue oxygenation. These findings suggest that the timing of CA4P treatments when used in conjunction with conventional anticancer therapies should be considered carefully.},

  doi          = {10.1016/j.ijrobp.2006.12.051},

  journal      = {International Journal of Radiation Oncology, Biology and Physics},

  number       = 1,

  volume       = 68,

  place        = {United States},

  year         = {Tue May 01 00:00:00 EDT 2007},

  month        = {Tue May 01 00:00:00 EDT 2007}

}

Copy to clipboard

Journal Article:

DOI: 10.1016/j.ijrobp.2006.12.051

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Tumor physiologic response to combretastatin A4 phosphate assessed by MRI

Journal Article Zhao Dawen ; Jiang Lan ; Hahn, Eric W. ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To evaluate the effect of the vascular targeting agent, combretastatin A4 phosphate, on tumor oxygenation compared with vascular perfusion/permeability. Methods and Materials: {sup 19}F MRI oximetry and dynamic contrast-enhanced (DCE)-MRI were used to monitor tumor oxygenation and perfusion/permeability in syngeneic 13762NF rat breast carcinoma. Results: A significant drop was found in the mean tumor pO{sub 2} (23 to 9 mm Hg, p <0.05) within 90 min after treatment (30 mg/kg of combretastatin A4 phosphate) and a further decrease was observed at 2 h (mean 2 mm Hg; p <0.01). The initial changes in pO{sub 2} in the central andmore »« less
DOI: 10.1016/j.ijrobp.2005.03.009
Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging

Journal Article McPhail, Lesley D. ; Department of Basic Medical Sciences, St. George's, University of London, London ; Griffiths, John R. D.Phil. ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To investigate the use of the transverse magnetic resonance imaging (MRI) relaxation rate R{sub 2}* (s{sup -1}) as a biomarker of tumor vascular response to monitor vascular disrupting agent (VDA) therapy. Methods and Materials: Multigradient echo MRI was used to quantify R{sub 2}* in rat GH3 prolactinomas. R{sub 2}* is a sensitive index of deoxyhemoglobin in the blood and can therefore be used to give an index of tissue oxygenation. Tumor R{sub 2}* was measured before and up to 35 min after treatment, and 24 h after treatment with either 350 mg/kg 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or 100 mg/kg combretastatin-A4-phosphatemore »« less
DOI: 10.1016/j.ijrobp.2007.08.025
Tumor Antivascular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Non-Small-Cell Lung Cancer

Journal Article Ng, Q.-S. ; Goh, Vicky ; Carnell, Dawn ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: The tumor vascular effects of radiotherapy and subsequent administration of the vascular disrupting agent combretastatin A4 phosphate (CA4P) were studied in patients with advanced non-small-cell lung cancer using volumetric dynamic contrast-enhanced computed tomography (CT). Patients and Methods: Following ethical committee approval and informed consent, 8 patients receiving palliative radiotherapy (27 Gy in six fractions, twice weekly) also received CA4P (50 mg/m{sup 2}) after the second fraction of radiotherapy. Changes in dynamic CT parameters of tumor blood volume (BV) and permeability surface area product (PS) were measured for the whole tumor volume, tumor rim, and center after radiotherapy alone andmore »« less
DOI: 10.1016/j.ijrobp.2006.11.028
In Vivo Near-Infrared Spectroscopy and Magnetic Resonance Imaging Monitoring of Tumor Response to Combretastatin A-4-Phosphate Correlated With Therapeutic Outcome

Journal Article Zhao Dawen, E-mail: Dawen.Zhao@UTSouthwestern.ed ; Chang Chenghui ; Kim, Jae G. ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To develop a combination treatment consisting of combretastatin A-4-phosphate (CA4P) with radiation based on tumor oxygenation status. Methods and Materials: In vivo near-infrared spectroscopy (NIRS) and diffusion-weighted (DW) magnetic resonance imaging (MRI) were applied to noninvasively monitor changes in tumor blood oxygenation and necrosis induced by CA4P (30 mg/kg) in rat mammary 13762NF adenocarcinoma, and the evidence was used to optimize combinations of CA4P and radiation treatment (a single dose of 5 Gy). Results: NIRS showed decreasing concentrations of tumor vascular oxyhemoglobin and total hemoglobin during the first 2 h after CA4P treatment, indicating significant reductions in tumor bloodmore »« less
DOI: 10.1016/j.ijrobp.2010.12.028
Preclinical Studies to Predict Efficacy of Vascular Changes Induced by Combretastatin A-4 Disodium Phosphate in Patients

Journal Article Nielsen, Thomas ; Department of Neuroradiology, Aarhus University Hospital, Aarhus ; Murata, Rumi ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To determine how combretastatin A-4 disodium phosphate (CA4DP) dose-dependent changes in radiation response of a C3H mouse mammary carcinoma relate to measurements of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters and how those mouse DCE-MRI results compare with published clinical DCE-MRI data. Methods and Materials: C3H mammary carcinomas grown in female CDF{sub 1} mice were treated when at 200 mm{sup 3} in size. Groups of mice were given graded radiation doses, either alone or followed 30 min later by an intraperitoneal injection of CA4DP, administered at doses of 10-250 mg/kg. The radiation dose producing local tumor control in 50%more »« less
DOI: 10.1016/j.ijrobp.2007.10.012

Similar Records